Gaussian model fitted of the number of dogs detections of SARS-CoV-2, depending on the cycle threshold (Ct) values of RT-qPCR tests for SARS-CoV-2. by Víctor M. Vidal-Martínez (18707335)

Relative expression (fold-change) of immune genes in LPS-stimulated peritoneal macrophages. by Chaiwat Monmai (6377270)

Effects of CFAMs on the proteins associated with NF-κB and MAPK pathways in RAW264.7 cells. by Chaiwat Monmai (6377270)

Effects of various concentrations of <i>Codium fragile</i> extracts. by Chaiwat Monmai (6377270)

Coumarin-Annelated Regioisomeric Heptahelicenes: Influence of Helicity on Excited-State Properties and Chiroptical Properties by Arindam Mukhopadhyay (1961227)

Relative expression (fold-change) of immune genes in mitogen-stimulated splenic lymphocytes. by Chaiwat Monmai (6377270)

Size distributions of ucfDNA molecules. by Meihui Chen (1670020)

Effects of different concentrations of CFAMs on peritoneal macrophage. by Chaiwat Monmai (6377270)

Comparison of human measures of motor learning across the Start phase (5 first games) and the Middle phase (5 middle games) of <i>Auto Orbit</i>. by Pierre Giovanni Gianferrara (11553077)

Schematic of the model used in this simulation. by Takahiro Kohsokabe (18078713)

Genetic and observational estimates of the influence of altering BMI on serum testosterone (T). by Joel Eriksson (149940)

Observational estimates. by Joel Eriksson (149940)

SYBR Green I-Background suppressor gametocytocidal assay. by Natalie G. Sanders (621904)

“…(F) Overall assay setup with five steps: 1. Culture and enrich gametocytes, 2. Incubate with drug for 48 hr, 3. …”

Diffuse reflectance versus radial distance per solid angle. by Chizhu Ding (813943)

Nemp1 supports erythroblasts enucleation. by Didier Hodzic (132944)

CPSF6-NLS chimeras confer virus-specific infectivity defects. by Nicholas Rohlfes (20577485)

Nemp1 localizes at the NE of hematopoietic cells and aggregates at NE openings. by Didier Hodzic (132944)

Image_1_IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.TIF by Hilde L. Orrem (5740313)

“…</p><p>Results: Our main findings were (i) Tocilizumab decreased C5aR1 and C5aR2 mRNA expression significantly (p < 0.001) and substantially (>50%) at day 2 and 3, whereas C3aR expression was unaffected. …”

Image_2_IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.TIF by Hilde L. Orrem (5740313)

“…</p><p>Results: Our main findings were (i) Tocilizumab decreased C5aR1 and C5aR2 mRNA expression significantly (p < 0.001) and substantially (>50%) at day 2 and 3, whereas C3aR expression was unaffected. …”

Table_1_IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.DOCX by Hilde L. Orrem (5740313)

“…</p><p>Results: Our main findings were (i) Tocilizumab decreased C5aR1 and C5aR2 mRNA expression significantly (p < 0.001) and substantially (>50%) at day 2 and 3, whereas C3aR expression was unaffected. …”